Biomimetic Implants and Technology

Eye%20contact2_edited.png
Eye%20contact4_edited.png

Biomimetics

Biomimetics is the emulation of the models, systems, and elements of nature for the purpose of solving complex human problems.*

At CorNeat Vision we harness unique characteristics of microstructures of the human body to develop biomimetic implants which mend and replace damaged tissue, while mimicking its function.

Our core platform technology, which was already validated in-vivo, enables permanent implants to bio-mechanically integrate with live tissue without triggering an adverse immune system response.

Our platform is a 100% synthetic non-degradable porous material that mimics the micro-structure of the Extracellular Matrix (ECM), the natural biological collagen mesh that provides structural and biochemical support to surrounding cells. When implanted, this material stimulates cellular proliferation leading to progressive tissue integration.

This technology enables us to develop implants that are:

  • 100% synthetic and therefore does not carry disease

  • Effectively bio-integrate and therefore heal faster

  • Do not rely on any type of harvested tissue and therefore scalable

CorNeat Vision’s platform technology has dozens of applications across diversified therapeutic fields. The platform material can be produced in various 2D and 3D forms enabling the following functions:

  •            Physical attachment of implants to tissue

  •            Concealment of implants & sensors

  •            Soft tissue repair and permanent reinforcement

  •            Fabrication of membranes and tissue barriers 

 

CorNeat Vision’s initial set of novel implants combine its biomimetic technology with innovative ideas to effectively address unmet needs in the areas of ophthalmology and periodontology. We are currently expanding our IP portfolio to additional fields of medicine.

*Vincent, Julian F. V.; et al. (22 August 2006). "Biomimetics: its practice and theory". Journal of the Royal Society Interface. 3 (9): 471–482. doi:10.1098/rsif.2006.0127. PMC 1664643. PMID 16849244.

corneat everpatch

CorNeat EverPatch

Synthetic Tissue Substitute

CorNeat KPro

Synthetic Cornea

corneat eshunt

CorNeat eShunt

Glaucoma Shunt

gPatch_no background.png

CorNeat gPatch

Synthetic Reinforcement Patch

Our Mission: Harness Biomimicry For Improving Health

CorNeat Vision strives to promote health and equality by promoting medical solutions widely accessible to vast global markets, including developing and impoverished countries. We offer innovative, permanent, convenient and affordable solutions by leveraging our unique biomimetic technology and R&D capabilities.

Our goal at CorNeat Vision is to innovate and grow, as well as leverage the power of partnerships to introduce biomimetic implants that aim to permanently resolve medical and surgical challenges in diversified therapeutic fields.

Finding solutions to medical problems is extremely challenging. CorNeat Vision promotes permanent solutions to medical problems through an active learning process, putting the physician's ease of use as one of our top priorities.

Untitled%20design%20(2)_edited.png
 

About CorNeat Vision

CorNeat Vision was established in December 2015 in order to develop and bring to market a scalable artificial solution for global corneal blindness which eliminates the dependency on donor tissue.

As our advisors were exposed to our extraordinary pre-clinical results, which demonstrated progressive and seamless tissue integration with our biomimetic non-degradable material, they requested pieces of this material for replacing the use of tectonic tissue grafts in other ophthalmic surgical procedures. Realizing the potential of our platform technology, we registered IP for additional devices in the ophthalmic space.

In order to fully exploit the business potential of our technology and to maximize its impact on human health we are expanding our IP and product portfolio and introducing solutions in additional fields of medicine. Our first such product is aimed at permanently resolving gingival recession and replace the current use of degradable tissue grafts.  

CorNeat Vision’s first two products, the CorNeat EverPatch (synthetic tissue substitute) and the CorNeat KPro (synthetic cornea), are in clinical trials and expected to receive initial marketing approval in 2021 and 2022, respectively.